CDRT15P8

Across TCGA pan-cancer cohorts, CDRT15P8 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated CDRT15P8 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CDRT15P8 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDRT15P8 expression acts as an unfavorable survival marker, although some lineages such as MESO and LGG show a favorable association.

LIHC, STAD, and MESO are the cancer types where CDRT15P8 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.391	0.579	<.001	105	view →
STAD	OS	Tertile	All	0.182	0.437	.009	54	view →
MESO	OS	Tertile	II,III,IV	0.823	0.362	.024	48	view →
UCS	DFS	Tertile	IV	0.132	0.718	.002	36	view →
READ	OS	Tertile	II,III,IV	0.287	0.829	.008	36	view →
KICH	DFS	Quartile	All	0.647	0.959	.009	19	view →
LGG	OS	Tertile	All	0.773	0.398	.022	9	view →
THYM	DFS	Tertile	III,IV	0.214	1.000	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CDRT15P8–LIHC (DFS)

Open the LIHC breakdown →